Ucb

UCB, a Pharmaceutical Preparation Manufacturing company based in Belgium, reported total emissions of approximately 873.9 million kg CO2e in 2025. This includes Scope 1 emissions of 22.19 million kg CO2e, Scope 2 (market-based) emissions of 15,000 kg CO2e, and Scope 3 emissions of 849.8 million kg CO2e.

Looking back, in 2024, UCB's total emissions were approximately 807.15 million kg CO2e, with Scope 1 at 21.72 million kg CO2e, Scope 2 (market-based) at 5,000 kg CO2e, and Scope 3 at 769.14 million kg CO2e. In 2023, the company's total emissions were approximately 85.33 million kg CO2e, comprising Scope 1 emissions of 20.55 million kg CO2e, Scope 2 (market-based) emissions of 1.62 million kg CO2e, and Scope 3 emissions of 63.17 million kg CO2e.

UCB has set several climate commitments. The company has validated Science-Based Targets (SBTi) with a near-term target to reduce absolute Scope 1 and 2 GHG emissions by 73% by 2030 from a 2019 base year. They also aim to reduce absolute Scope 3 GHG emissions from fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, upstream leased assets, and end-of-life treatment of sold products by 48% within the same timeframe (2019-2030). Furthermore, UCB commits that 80% of its suppliers by emissions, covering purchased goods and services, will have science-based targets by 2028.

For long-term goals, UCB is committed to reaching net-zero greenhouse gas emissions across the value chain by 2045. This includes reducing absolute Scope 1 and 2 GHG emissions by 90% by 2045 from a 2019 base year, and reducing absolute Scope 3 GHG emissions from purchased goods and services, fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, upstream leased assets, and end-of-life treatment of sold products by 90% within the same timeframe.